title: [Recent advance of chemotherapy in gastric cancer].
abstract: Chemotherapy for gastric cancer is improving continuously through conducting randomized clinical trials and developing new anti-cancer drugs. Patient survivals are prolonged and their QOL are maintained for longer periods. S-1 and CDDP chemotherapy is recommended for unresectable advanced disease, and adjuvant chemotherapy with S-1 is also recommended for stage II/III disease. Recently, combination chemotherapy with trastuzumab has been shown to be effective for HER2 positive gastric cancer. Conversely, new chemotherapeutic agents are needed for peritoneal metastasis patients, elderly patients, and patients with a poor organ function. Neo-adjuvant chemotherapy is expected to improve the overall survival for initially unresectable gastric cancer patients. Collaboration between Japan and Korea is expected to accelerate clinical trials to resolve these unmet needs.
authors.affiliation: Gastrointestinal Medical Oncology Division, National Cancer Center Hospital.
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Terazawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimada
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage; D010446:Peptide Fragments / Q000032:analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002945:Cisplatin; D004338:Drug Combinations; D010094:Oxonic Acid; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases; D005641:Tegafur; D000068878:Trastuzumab; C561872:HER2 peptide (369-377); C079198:S 1 (combination)